OBJECTIVE: To study the role of the glucocorticoid receptor (GR) signal pathway and downstream cytokine interleukin-6 (IL-6) in androgen-independent growth of prostate cancer (PC). METHODS: The human androgen-dependent PC (ADPC) cell line LNCaP and androgen-independent PC (AIPC) cell line DU145 were cultured in vitro. Immunocytochemistry was used to examine the expression of the androgen receptor (AR), GR, HSP90 and IL-6. The GR antagonist RU486 was used to treat cultured cells, and the effects of RU486 on the proliferation of both cell lines were analyzed by MTT assay. Expression of HSP90 and IL-6 mRNA and protein was assessed by RT-PCR and Western blots, respectively. RESULTS: LNCaP cells were AR-positive and GR-negative, whereas DU145 cells were GR-positive and AR-negative. The expression of HSP90 and IL-6 in DU145 cells were significantly stronger than that in LNCaP cells (p < 0.01). RU486 had no obvious effects on the growth of LNCaP cells, but exerted a significant time- and dose-dependent growth inhibition on DU145 cells at doses as low as 0.1 micromol/l. RU486 treatment of DU145 cells also resulted in a dose-dependent decrease in the expression of HSP90 and IL-6 mRNA and protein. CONCLUSIONS: The GR signal pathway may be the main survival pathway for DU145 cells. Abnormal hyperactivation of the GR signal pathway and its promoting the expression of HSP90 and IL-6 contribute to the progression of ADPC to AIPC after androgen ablation. (c) 2008 S. Karger AG, Basel.
OBJECTIVE: To study the role of the glucocorticoid receptor (GR) signal pathway and downstream cytokine interleukin-6 (IL-6) in androgen-independent growth of prostate cancer (PC). METHODS: The human androgen-dependent PC (ADPC) cell line LNCaP and androgen-independent PC (AIPC) cell line DU145 were cultured in vitro. Immunocytochemistry was used to examine the expression of the androgen receptor (AR), GR, HSP90 and IL-6. The GR antagonist RU486 was used to treat cultured cells, and the effects of RU486 on the proliferation of both cell lines were analyzed by MTT assay. Expression of HSP90 and IL-6 mRNA and protein was assessed by RT-PCR and Western blots, respectively. RESULTS: LNCaP cells were AR-positive and GR-negative, whereas DU145 cells were GR-positive and AR-negative. The expression of HSP90 and IL-6 in DU145 cells were significantly stronger than that in LNCaP cells (p < 0.01). RU486 had no obvious effects on the growth of LNCaP cells, but exerted a significant time- and dose-dependent growth inhibition on DU145 cells at doses as low as 0.1 micromol/l. RU486 treatment of DU145 cells also resulted in a dose-dependent decrease in the expression of HSP90 and IL-6 mRNA and protein. CONCLUSIONS: The GR signal pathway may be the main survival pathway for DU145 cells. Abnormal hyperactivation of the GR signal pathway and its promoting the expression of HSP90 and IL-6 contribute to the progression of ADPC to AIPC after androgen ablation. (c) 2008 S. Karger AG, Basel.
Authors: Jacob Kach; Tiha M Long; Phillip Selman; Eva Y Tonsing-Carter; Maria A Bacalao; Ricardo R Lastra; Larischa de Wet; Shane Comiskey; Marc Gillard; Calvin VanOpstall; Diana C West; Wen-Ching Chan; Donald Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz Journal: Mol Cancer Ther Date: 2017-04-20 Impact factor: 6.261
Authors: Martin Ligr; Yirong Li; Susan K Logan; Samir Taneja; Jonathan Melamed; Hebert Lepor; Michael J Garabedian; Peng Lee Journal: J Urol Date: 2012-07-21 Impact factor: 7.450
Authors: Masis Isikbay; Kristen Otto; Steven Kregel; Jacob Kach; Yi Cai; Donald J Vander Griend; Suzanne D Conzen; Russell Z Szmulewitz Journal: Horm Cancer Date: 2014-03-11 Impact factor: 3.869
Authors: Donghao Lu; Jennifer A Sinnott; Lorelei A Mucci; Katja Fall; Unnur Valdimarsdóttir; Fang Fang; Travis Gerke; Svitlana Tyekucheva; Michelangelo Fiorentino; Mats Lambe; Howard D Sesso; Christopher J Sweeney; Kathryn M Wilson; Edward L Giovannucci; Massimo Loda Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531
Authors: Frank Claessens; Christine Helsen; Stefan Prekovic; Thomas Van den Broeck; Lien Spans; Hendrik Van Poppel; Steven Joniau Journal: Nat Rev Urol Date: 2014-09-16 Impact factor: 14.432
Authors: Anthony V Serritella; Daniel Shevrin; Elisabeth I Heath; James L Wade; Elia Martinez; Amanda Anderson; Joseph Schonhoft; Yen-Lin Chu; Theodore Karrison; Walter M Stadler; Russell Z Szmulewitz Journal: Clin Cancer Res Date: 2022-04-14 Impact factor: 13.801